Migraine Briefs

Chronic migraine: Efficacy and safety of CGRP slightly better than botulinum toxin


 

Key clinical point: Calcitonin gene-related peptide (CGRP) monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesic intake in patients with chronic migraine (CM). Treatment-related serious adverse events (SAEs) were lower with CGRP monoclonal antibody.

Major finding: CGRP monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesics intake (weighted mean difference, −1.31; P = .02113). Treatment-related SAEs were lower with CGRP monoclonal antibody vs. botulinum toxin (relative risk, 0.505; P = .001).

Study details: Findings are from a meta-analysis of 10 studies including 6,325 patients, which performed indirect treatment comparison between CGRP monoclonal antibody and botulinum toxin for prophylactic treatment of CM.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: Lu J et al. Front Pharmacol. 2021 May 3. doi: 10.3389/fphar.2021.631204 .

Recommended Reading

Telemedicine for headache visits had high patient satisfaction
Migraine ICYMI
Almost half of patients with migraine are reluctant to seek care
Migraine ICYMI
Combination therapy may benefit patients with migraine
Migraine ICYMI
A large proportion of migraine patients are not offered preventive treatment
Migraine ICYMI
e-TNS device passes at-home test
Migraine ICYMI
Chronic headache pain in veterans linked to suicide attempts
Migraine ICYMI
Migraine linked to more COVID-19 infections, symptoms but less health care utilization
Migraine ICYMI
Ubrogepant effective for acute migraine even with preventive monoclonal antibody therapy
Migraine ICYMI
Moving more, sitting less vital for migraine patients
Migraine ICYMI
Erenumab reduces migraine attacks and not just migraine days
Migraine ICYMI